The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
ApexOnco Front Page
Recent articles
BeOne's degrader BG-60366 appears to have been discontinued.
Bristol will test the bispecific in two new lung indications.
A phase 1 study of OKI-219 reads out imminently.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
After Genmab’s exit two more ADCs enter human trials.
A new phase 3, Manifest-3, will start in April to support US filing.
